Search

Your search keyword '"Rita R. Alloway"' showing total 124 results

Search Constraints

Start Over You searched for: Author "Rita R. Alloway" Remove constraint Author: "Rita R. Alloway" Topic kidney transplantation Remove constraint Topic: kidney transplantation
124 results on '"Rita R. Alloway"'

Search Results

1. Early Corticosteroid Cessation vs Long-term Corticosteroid Therapy in Kidney Transplant Recipients: Long-term Outcomes of a Randomized Clinical Trial.

2. YSPSL (rPSGL-Ig) for improvement of early renal allograft function: a double-blind, placebo-controlled, multi-center Phase IIa study.

3. Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients.

4. Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients.

5. Simultaneous corticosteroid avoidance and calcineurin inhibitor minimization in renal transplantation.

6. One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-InfeCted kidneys (MYTHIC) Trial

7. mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28− Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection

8. Rabbit anti‐thymocyte globulin for the prevention of acute rejection in kidney transplantation

9. A call for transplant stewardship: The need for expanded evidence‐based evaluation of induction and biologic‐based cost‐saving strategies in kidney transplantation and beyond

10. Chronopharmacokinetics and Food Effects of Single-Dose LCP-Tacrolimus in Healthy Volunteers

11. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection

12. Impact of Induction Therapy on Circulating T Follicular Helper Cells and Subsequent Donor-Specific Antibody Formation After Kidney Transplant

13. Reducing Donor-specific Antibody During Acute Rejection Diminishes Long-term Renal Allograft Loss: Comparison of Early and Late Rejection

14. Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: A prospective, randomized multicenter trial

15. Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients

16. A prospective, iterative, adaptive trial of carfilzomib-based desensitization

17. Incorporating Patients’ Values and Preferences Into Decision Making About Transplantation of HCV-Naïve Recipients With Kidneys From HCV-Viremic Donors: A Feasibility Study

18. Eculizumab and Belatacept for De Novo Atypical Hemolytic Uremic Syndrome Associated With CFHR3-CFHR1 Deletion in a Kidney Transplant Recipient: A Case Report

19. Absence of the Effect of Pretransplant Body Mass Index on Post Kidney Transplant Outcomes

20. Use of HCV Ab+/NAT- donors in HCV naïve renal transplant recipients to expand the kidney donor pool

21. Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values

22. Acute Rejection Clinically Defined Phenotypes Correlate With Long-term Renal Allograft Survival

23. Case Report: Successful Living Donor Kidney Transplantation in a Highly Human Leukocyte Antigen-Sensitized Recipient With a Positive Cytotoxic Crossmatch Using Bortezomib-Based Desensitization Without Intravenous Immunoglobulin

24. Complete Remission of Post-transplantation Recurrence of Focal Segmental Glomerulosclerosis With the Use of Adrenocorticotrophic Hormone Gel: Case Report

25. Prospective Iterative Trial of Proteasome Inhibitor-Based Desensitization

26. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial

27. Laparoscopic sleeve gastrectomy improves renal transplant candidacy and posttransplant outcomes in morbidly obese patients

28. Desensitization in kidney transplantation: review and future perspectives

29. Acute Rejection Characteristics From a Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Early Corticosteroid Withdrawal

30. A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study

31. A Randomized Pharmacokinetic Study of Generic Tacrolimus Versus Reference Tacrolimus in Kidney Transplant Recipients

32. Proteasome Inhibition for Antibody-Mediated Allograft Rejection

33. Proteasome inhibitor treatment of antibody-mediated allograft rejection

34. Early and Late Acute Antibody-Mediated Rejection Differ Immunologically and in Response to Proteasome Inhibition

35. Four-year experience with tacrolimus once-daily prolonged release in patients from phase II conversion and de novo kidney, liver, and heart studies

36. Proteasome Inhibitor-Based Primary Therapy for Antibody-Mediated Renal Allograft Rejection

37. Proteasome inhibition for antibody-mediated rejection

38. A Prospective Trial of a Steroid-Free/Calcineurin Inhibitor Minimization Regimen in Human Leukocyte Antigen (HLA)-Identical Live Donor Renal Transplantation

39. Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection

40. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study

41. Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: comparison of early steroid withdrawal and chronic steroids

42. Renal Transplantation in High-Risk Patients

43. LCPT once-daily extended-release tacrolimus tablets versus twice-daily capsules: a pooled analysis of two phase 3 trials in important de novo and stable kidney transplant recipient subgroups

44. Case Report: Hemolytic Anemia Following Deceased Donor Renal Transplantation Associated With Tranexamic Acid Administration for Disseminated Intravascular Coagulation

45. A Banff Component Scoring-based Histologic Assessment of Bortezomib-based Antibody-mediated Rejection Therapy

46. A Prospective, Randomized, Multicenter Study Evaluating the Safety and Efficacy of Two Dosing Regimens of Daclizumab Compared to No Antibody Induction in Simultaneous Kidney–Pancreas Transplantation: Results at 3 Years

47. Analysis of Factors that Influence Survival with Post-Transplant Lymphoproliferative Disorder in Renal Transplant Recipients: The Israel Penn International Transplant Tumor Registry Experience

48. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study1

49. Polyomavirus in kidney and kidney--pancreas transplant recipients

50. Thymoglobulin for induction or rejection therapy in pancreas allograft recipients: a single centre experience

Catalog

Books, media, physical & digital resources